Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed carcinoma of the cervix, including any of the following
subtypes:

- Squamous cell carcinoma

- Adenocarcinoma

- Adenosquamous cell carcinoma

- Must meet one of the following criteria:

- Persistent or relapsed inoperable disease after radical radiotherapy within the
irradiated pelvis

- Relapse after radical hysterectomy (after radical radiotherapy to pelvis, if
appropriate)

- Extra pelvic metastases

- Primary stage IVB disease

- Not suitable for potentially curative surgical procedure

- Measurable disease in ≥ 1 marker site

- No CNS disease, including brain metastases, within the past 6 months

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- Life expectancy > 12 weeks

- Hemoglobin ≥ 10 g/dL

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Calculated creatinine clearance ≥ 35 mL/min

- No proteinuria > 1+ on dipstick (on 2 consecutive dipsticks not less than 1 week
apart), unless urinary protein is < 1.5 g in a 24-hour period

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT or AST ≤ 2.5 times ULN (≤ 5 times ULN if hepatic metastases present)

- Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN if hepatic metastases present)

- Prothrombin ratio (PTR)/INR ≤ 1.5 OR PTR/INR 2.0-3.0 for patients on stable dose of
anticoagulant

- Partial thromboplastin time < 1.2 times control

- No history of a nervous or psychiatric disorder that would prevent informed consent
and compliance

- No prior malignancy within the past 5 years, except for successfully treated basal
cell skin cancer or in-situ breast cancer

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for ≥ 6 months after
completion of study treatment

- No uncontrolled infection, defined as infection that cannot be resolved readily with
antibiotics prior to trial entry

- No history of significant gastrointestinal impairment, as judged by the Investigator,
that would significantly affect the absorption of cediranib maleate

- No history of pelvic fistula

- No history of inflammatory bowel disease

- No sub-acute or acute intestinal obstruction

- No significant traumatic injury within the past 4 weeks

- No non-healing wound, ulcer, or bone fracture

- No active bleeding

- No history or evidence of thrombotic or hemorrhagic disorders

- No uncontrolled seizures, cerebrovascular accident, transient ischemic attack, or
subarachnoid hemorrhage within the past 6 months

- No significant cardiovascular disease, including any of the following:

- Arterial thrombotic event within the past 12 months

- Angina within the past 6 months

- History of poorly controlled or uncontrolled hypertension or resting BP >
150/100 mm Hg in the presence or absence of a stable regimen of
anti-hypertensive therapy within the past 6 months

- NYHA class II-IV congestive heart failure

- Peripheral vascular disease ≥ grade 3 or cardiac arrhythmia requiring medication

- Prolonged QTc (corrected) interval of > 470 ms on ECG or a family history of
long QT syndrome

- Patients with rate-controlled atrial fibrillation are eligible

- Not requiring intravenous nutritional support

- No preexisting sensory or motor neuropathy ≥ grade 2

- No history or clinical suspicion of spinal cord compression

- No known hypersensitivity to carboplatin or paclitaxel

- No evidence of any other disease, metabolic dysfunction, physical examination
finding, or laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates the use of an investigational drug or puts the patient at high
risk for treatment-related complications

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No unresolved toxicity ≥ CTC grade 2 from prior systemic anti-cancer therapy, except
hematological toxicity or alopecia

- No prior chemotherapy, except cisplatin administered along with radiotherapy as
primary treatment

- No major surgery within 28 days or anticipated while on study

- More than 2 weeks since prior and no concurrent potent inhibitors of CYP3A4 and 2C8,
including any of the following:

- Amiodarone

- Clarithromycin

- Erythromycin

- Simvastatin

- Atorvastatin

- Lovastatin

- Montelukast sodium

- Verapamil

- Ketoconazole

- Miconazole

- Indinavir (and other antivirals)

- Diltiazem

- No concurrent grapefruit juice or St. John wort